Par Drugs And Chemicals Limited has informed the Exchange regarding Outcome of Board Meeting held on May 14, 2026.
PAR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Par Drugs and Chemicals Limited announced its Q4 and full-year FY2025-26 audited standalone results. Full-year revenue grew 4.4% to Rs. 10,765.63 Lakhs (vs Rs. 10,312.38 Lakhs in FY25), but profitability declined — PBT fell 3.5% to Rs. 1,730.16 Lakhs and PAT dropped 1.9% to Rs. 1,310.86 Lakhs. EPS for FY26 stood at Rs. 10.65, down from Rs. 10.86 in the prior year. The auditor issued an unmodified opinion. Critically, the auditor's report highlights a Key Audit Matter: SEBI issued an ex-parte interim order and a confirmatory order restraining the company's proposed business transfer arrangement (slump sale of its primary business to a related party), and the company is evaluating legal remedies including challenging the order. Cash position strengthened to Rs. 4,184.29 Lakhs (from Rs. 2,757.72 Lakhs) with zero borrowings, but trade receivables nearly doubled to Rs. 1,671.41 Lakhs. The board approved investment authority up to Rs. 90 Crore in liquid funds and renewed banking facilities of Rs. 161 Lakh with Kotak Mahindra Bank.
FY26 revenue grew modestly but bottom-line declined, signaling margin pressure. The SEBI restraining order on the business transfer is a significant regulatory risk that could disrupt the company's strategic plans and future operations. Investors should monitor the legal outcome closely as it affects the company's going concern assessment.